Peptide Therapy: What the Science Actually Says

What is peptide therapy?

Peptide therapy is the use of peptides — short chains of amino acids — as therapeutic agents to treat disease or optimize physiological function. The term covers a broad spectrum: from rigorously tested, FDA-approved medications prescribed by physicians (insulin, semaglutide, teriparatide) to investigational compounds in clinical trials to unregulated “research peptides” sold online without quality assurance. Understanding where any given peptide falls on this spectrum is essential for making informed decisions.

As of 2026, there are approximately 80+ FDA-approved peptide drugs on the market, with hundreds more in clinical trials. Peptides represent one of the fastest-growing segments of the pharmaceutical industry, with the global peptide therapeutics market projected to exceed $50 billion by 2027. This growth is driven largely by GLP-1 receptor agonists for diabetes and obesity, but peptides are used across virtually every therapeutic area.

FDA-approved peptide drugs: what actually works

Metabolic disease (diabetes and obesity)

This is where peptide therapy has its strongest evidence base. Insulin (the original peptide drug, first used in 1922) remains the cornerstone of type 1 diabetes treatment. Semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), liraglutide (Victoza/Saxenda), and exenatide (Byetta/Bydureon) are GLP-1 receptor agonists for type 2 diabetes and/or obesity with extensive clinical trial data demonstrating efficacy and safety in tens of thousands of patients.

Bone health

Teriparatide (Forteo) is a recombinant fragment of parathyroid hormone (amino acids 1–34) that is one of the few drugs that actually builds new bone rather than merely slowing bone loss. It is approved for severe osteoporosis. Calcitonin (Miacalcin) from salmon calcitonin is used for postmenopausal osteoporosis and Paget’s disease.

Pain management

Ziconotide (Prialt), derived from cone snail venom, is an N-type calcium channel blocker approved for severe chronic pain delivered intrathecally. It provides non-opioid analgesia without tolerance or addiction risk.

Endocrine disorders

Octreotide (Sandostatin) and lanreotide (Somatuline) are somatostatin analogs used for acromegaly and neuroendocrine tumors. Desmopressin is a synthetic vasopressin analog for diabetes insipidus and bedwetting. Goserelin (Zoladex) and leuprolide (Lupron) are GnRH agonists for prostate cancer, endometriosis, and precocious puberty.

Oncology

Lutetium-177 dotatate (Lutathera) is a radiolabeled somatostatin analog for peptide receptor radionuclide therapy (PRRT) of gastroenteropancreatic neuroendocrine tumors. It delivers targeted radiation to tumor cells expressing somatostatin receptors, representing one of the most elegant applications of peptide biology in cancer treatment.

Research peptides: what the evidence actually shows

Beyond FDA-approved drugs, a large market exists for “research peptides” — compounds that are sold for laboratory research purposes but are widely used by individuals for self-experimentation. It is critical to understand that most of these compounds have limited or no human clinical trial data, uncertain purity from unregulated sources, and potential safety risks that have not been characterized.

BPC-157

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a protein found in human gastric juice. It has shown wound healing, tendon repair, and anti-inflammatory effects in numerous animal studies. However, as of 2026, there are virtually no published controlled human clinical trials. The FDA placed BPC-157 on its Category 2 list of bulk drug substances that present potential safety concerns for compounding. The animal data is genuinely interesting, but the gap between rodent studies and human evidence is substantial.

TB-500 (Thymosin Beta-4 fragment)

TB-500 is a 43-amino-acid peptide identical to the active region of thymosin beta-4, a naturally occurring peptide involved in wound healing, tissue repair, and angiogenesis. Thymosin beta-4 has some human clinical data — it has been studied in ophthalmic clinical trials for corneal wound healing with promising results. However, TB-500 (the synthetic fragment) has not undergone the same regulatory pathway and is sold as a research compound.

Growth hormone secretagogues

Peptides like ipamorelin, CJC-1295, tesamorelin, and sermorelin stimulate the pituitary to release growth hormone. Tesamorelin (Egrifta) is actually FDA-approved — for HIV-associated lipodystrophy. Sermorelin was previously approved as a diagnostic agent. Ipamorelin and CJC-1295 are research compounds without FDA approval. These peptides increase GH/IGF-1 levels, which may benefit body composition, but long-term safety data (particularly regarding cancer risk from sustained IGF-1 elevation) is limited for the unapproved variants.

Selank and Semax

Selank and semax are heptapeptides developed at the Russian Academy of Sciences for anxiolytic and nootropic applications, respectively. Both are approved as nasal sprays in Russia but are not FDA-approved. Peer-reviewed research exists but is largely from Russian-language journals, and Western clinical validation is limited.

The compounding pharmacy landscape

In the United States, compounding pharmacies have played a significant role in peptide therapy by preparing customized peptide formulations. During the GLP-1 drug shortage of 2023–2024, compounding pharmacies produced semaglutide and tirzepatide under FDA shortage provisions. The FDA’s February 2025 announcement that the semaglutide shortage was “resolved” triggered regulatory changes that restricted compounding of these specific drugs, though compounding of other peptides continues under existing 503A and 503B regulatory frameworks.

For practitioners and patients working with compounding pharmacies, key quality indicators include: 503B outsourcing facility registration (higher regulatory standard than 503A), third-party potency and sterility testing, proper GMP compliance documentation, and Certificates of Analysis (COAs) from qualified laboratories. The distinction between a regulated compounding pharmacy and an offshore “research chemical” supplier is enormous in terms of product quality and patient safety.

How to evaluate peptide therapy claims

The peptide space is rife with exaggerated claims on social media and from commercial sources. A framework for evaluating any peptide therapy claim:

Is it FDA-approved? If yes, robust clinical evidence exists. Check the drug label at DailyMed for prescribing information.

Are there published human clinical trials? Search PubMed and ClinicalTrials.gov. Look for randomized, placebo-controlled trials (RCTs) — not case reports or animal studies alone.

What is the source? FDA-regulated pharmacy vs. offshore “research chemical” supplier. Purity, sterility, and accurate dosing cannot be assumed from unregulated sources.

What is the route of administration? Most peptides require injection because they are destroyed by digestive enzymes. Claims of oral peptide supplements with systemic effects (other than collagen peptides for skin/joints and oral semaglutide with SNAC) should be viewed skeptically.

Peptide therapy in dermatology and aesthetics

Dermatology is one of the most active areas for peptide application, spanning both FDA-regulated products and the cosmeceutical market. Copper peptide GHK-Cu is the most studied matrikine in skin care. This naturally occurring tripeptide (Gly-His-Lys bound to copper) was first identified by Loren Pickart in the 1970s in human plasma, where it declines with age. GHK-Cu stimulates collagen synthesis (types I and III), promotes glycosaminoglycan production, enhances wound healing, and has anti-inflammatory and antioxidant effects. It is available in topical formulations and is used in post-procedure skin recovery protocols.

Palmitoyl pentapeptide-4 (Matrixyl, palmitoyl-KTTKS) is the most commercially successful cosmeceutical peptide. It is a fragment of collagen type I propeptide that signals fibroblasts to produce new collagen, and is found in hundreds of anti-aging skincare products globally. Acetyl hexapeptide-3 (Argireline) is marketed as a “topical Botox” — it is a fragment of SNAP-25 that inhibits SNARE complex formation, theoretically reducing neuromuscular junction signaling and thus reducing expression lines. Clinical evidence for its efficacy is limited compared to injectable botulinum toxin, but it demonstrates the principle of using peptides to modulate specific molecular targets in skin.

In clinical dermatology, peptide-based treatments extend to wound healing (thymosin beta-4 analogs), scar management, and hair growth stimulation (copper peptides, PTD-DBM). The Seoul Skin Concierge and similar medical aesthetics services increasingly incorporate peptide protocols into comprehensive skin rejuvenation programs, combining topical peptides with professional treatments like microneedling (which enhances peptide penetration) and LED therapy.

Peptides in sports and performance

The use of peptides in sports and fitness is widespread but largely unregulated and controversial. The World Anti-Doping Agency (WADA) prohibits several peptide classes in competition: growth hormone-releasing peptides (GHRPs like GHRP-6, GHRP-2, hexarelin), growth hormone secretagogues (ipamorelin, CJC-1295), GH itself, IGF-1, and mechano growth factor (MGF). These substances are banned because they enhance muscle growth, recovery, and performance beyond natural physiological limits.

The most commonly used performance peptides in the fitness community include BPC-157 and TB-500 (for injury recovery), ipamorelin and CJC-1295 (for growth hormone stimulation), and AOD-9604 (a fragment of growth hormone studied for fat loss). It is important to note that none of these are FDA-approved for performance or recovery indications, the vast majority of evidence comes from animal studies, quality control from online sources is unreliable (studies have found that many “research peptides” contain incorrect quantities, wrong peptides, or bacterial contamination), and legal risks vary by jurisdiction.

Peptide delivery: how they get into the body

The route of administration is a critical consideration in peptide therapy, because peptides face two fundamental barriers: enzymatic degradation (proteases in the gut, blood, and tissues rapidly break down unmodified peptides) and poor membrane permeability (most peptides are too large and too hydrophilic to cross cell membranes or the intestinal epithelium). The available delivery routes, from most to least common in clinical practice:

Subcutaneous injection: The standard route for most peptide drugs (insulin, semaglutide, tirzepatide). The peptide is injected into the fatty tissue beneath the skin, where it is absorbed into the bloodstream over hours. Modern pen injectors (FlexPen, KwikPen, autoinjectors) have made self-injection routine for millions of patients.

Intravenous (IV) infusion: Used for peptides requiring immediate systemic delivery (octreotide for carcinoid crisis, vasopressin for septic shock). Provides 100% bioavailability but requires clinical settings.

Intrathecal delivery: Direct injection into cerebrospinal fluid via an implanted pump. Used for ziconotide (Prialt), which cannot cross the blood-brain barrier. Reserved for severe chronic pain unresponsive to other treatments.

Intranasal: Nasal mucosa provides a relatively thin epithelial barrier with rich blood supply. Used for desmopressin (DDAVP), oxytocin (Syntocinon nasal spray, used off-label for social anxiety research), and calcitonin (Miacalcin nasal spray). Selank and semax are administered intranasally in Russia.

Oral: The most patient-friendly but most technically challenging route. Oral semaglutide (Rybelsus) is the landmark achievement, using the SNAC absorption enhancer. Collagen peptides are absorbed orally because they are very small (di- and tripeptides) and use active transport via the PepT1 intestinal transporter. Most other peptides are destroyed in the GI tract before reaching systemic circulation. Ongoing research into oral peptide delivery includes permeation enhancers, nanoparticle encapsulation, enteric coatings, and mucoadhesive formulations.

Topical: The skin is a significant barrier to peptide absorption. Topical peptides used in cosmetics (GHK-Cu, Matrixyl, Argireline) have local effects in the epidermis and upper dermis but limited systemic absorption. Transdermal peptide delivery using microneedle patches is an active area of research that could eventually enable needle-free administration of peptide drugs like insulin and semaglutide.

The regulatory landscape

Peptide therapy exists in a complex regulatory environment. FDA-approved peptide drugs undergo the same rigorous review process as any pharmaceutical: preclinical safety studies, Phase I–III clinical trials involving thousands of patients, manufacturing quality standards (GMP), and post-marketing surveillance. These drugs have well-characterized safety profiles and known efficacy.

Compounding pharmacies operate under either Section 503A (traditional compounding for individual prescriptions) or Section 503B (outsourcing facilities that can produce larger batches without individual prescriptions but must follow cGMP standards and FDA inspection). The February 2025 FDA announcement regarding the resolution of the semaglutide shortage significantly impacted the compounding landscape, but many other peptides remain available through legitimate compounding channels.

Research peptides sold online for “laboratory research only” occupy a gray area. They are not FDA-approved for human use, are not subject to pharmaceutical manufacturing standards, and their sale for human consumption is technically illegal in the United States. Despite this, they are widely available and widely used. The quality, purity, and sterility of these products is highly variable and essentially unverifiable by the end consumer.

Key terminology

← Browse the Full Dictionary

Part of the PeptideBond.com education network